|
Corbus Pharmaceuticals Holdings ، Inc. (CRBP) تقييم DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Bundle
استكشف الآفاق المالية لـ Corbus Pharmaceuticals Holdings ، Inc. (CRBP) مع حاسبة DCF سهلة الاستخدام! أدخل افتراضاتك للنمو والهوامش والتكاليف لحساب القيمة الجوهرية لـ Corbus Pharmaceuticals Holdings ، Inc. (CRBP) وتعزيز استراتيجية الاستثمار الخاصة بك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.1 | 3.9 | .9 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -89.11 | -77.61 | -100 | 0 | -66.68 | -66.68 | -66.68 | -66.68 | -66.68 |
| EBITDA | -76.4 | -121.7 | -55.0 | -38.7 | -44.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -211.28 | -3090.65 | -6234.59 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | 1.2 | 1.7 | 1.6 | 1.5 | .6 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 3.4 | 43.03 | 185.92 | 100 | 100 | 69.29 | 69.29 | 69.29 | 69.29 | 69.29 |
| EBIT | -77.6 | -123.4 | -56.6 | -40.2 | -45.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -214.69 | -3133.68 | -6420.51 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 31.7 | 85.4 | 97.6 | 59.2 | 20.9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.7 | 2.6 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 7.42 | 65.49 | 0 | 100 | 100 | 54.58 | 54.58 | 54.58 | 54.58 | 54.58 |
| Inventories | -2.7 | .4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | -7.42 | 8.89 | 0 | 100 | 100 | 40.29 | 40.29 | 40.29 | 40.29 | 40.29 |
| Accounts Payable | 11.1 | 7.4 | 1.8 | 2.2 | 3.2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 30.69 | 187.47 | 202.14 | 100 | 100 | 86.14 | 86.14 | 86.14 | 86.14 | 86.14 |
| Capital Expenditure | -2.7 | -.5 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -7.59 | -12.31 | -6.14 | 100 | 100 | -5.21 | -5.21 | -5.21 | -5.21 | -5.21 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -75.1 | -123.4 | -56.5 | -53.0 | -45.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -65.5 | -128.8 | -57.6 | -51.2 | -43.4 | -3.2 | .0 | .0 | .0 | .0 |
| WACC, % | 15.31 | 15.48 | 15.47 | 15.48 | 15.48 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | 7 | |||||||||
| Equity Value | -10 | |||||||||
| Diluted Shares Outstanding, MM | 4 | |||||||||
| Equity Value Per Share | -2.29 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real CRBP financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Corbus Pharmaceuticals’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Data: Access to Corbus Pharmaceuticals' historical financial statements and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Monitor the intrinsic value of Corbus Pharmaceuticals recalculating instantly.
- Intuitive Visual Outputs: Dashboard charts illustrate valuation results and essential metrics clearly.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Corbus Pharmaceuticals data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Corbus Pharmaceuticals' intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Corbus Pharmaceuticals (CRBP)?
- Comprehensive Tool: Incorporates DCF, WACC, and financial ratio analyses tailored for Corbus Pharmaceuticals.
- Customizable Inputs: Modify yellow-highlighted cells to explore various financial scenarios for (CRBP).
- Detailed Insights: Automatically computes Corbus Pharmaceuticals' intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on (CRBP).
Who Should Use Corbus Pharmaceuticals Holdings, Inc. (CRBP)?
- Pharmaceutical Students: Explore drug development processes and apply them using real-world data.
- Researchers: Integrate innovative models into your studies or clinical research.
- Investors: Evaluate your investment strategies and analyze valuation trends for Corbus Pharmaceuticals.
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Healthcare Entrepreneurs: Understand how public biotech companies like Corbus are assessed and valued.
What the Template Contains
- Preloaded CRBP Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.